Gynecologic Cancer

Rubraca’s Benefit in Ovarian Cancer Hinges on Platinum Status, Previous Therapy

Charles Bankhead

June 2017, Vol 8, No 3 - Gynecologic Cancer

National Harbor, MD—Patients with relapsed high-grade ovarian cancer with BRCA mutation derived the greatest benefit from the poly ADP-­ribose polymerase (PARP) inhibitor rucaparib (Rubraca) if their disease remained platinum sensitive, a new analysis of a large phase 2 clinical trial showed, as reported at the 2017 Society of Gynecologic Oncology meeting. [ Read More ]